Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTS · Real-Time Price · USD
2.240
-0.060 (-2.61%)
Nov 4, 2024, 4:00 PM EST - Market closed
Company Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States.
The company’s Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Alpha Tau Medical Ltd.
Country | Israel |
Founded | 2015 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 121 |
CEO | Uzi Sofer |
Contact Details
Address: Kiryat Hamada Street 5 Jerusalem, 9777605 Israel | |
Phone | 972 3 577 4115 |
Website | alphatau.com |
Stock Details
Ticker Symbol | DRTS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001871321 |
CUSIP Number | M0740A108 |
ISIN Number | IL0011839383 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Uzi Sofer | Chief Executive Officer and Chairman |
Raphi Levy | Chief Financial Officer |
Amnon Gat | Chief Operations Officer |
Peter M. Melnyk | Chief Commercial Officer |
Dr. Robert B. Den M.D. | Chief Medical Officer and Member of Scientific Advisory Board |
Ronen Segal | Chief Technology Officer |
Prof. Yona Keisari | Chief Scientific Officer and Member of Scientific Advisory board |
Rebecca Becker | Vice President of legal |
Prof. Itzhak Kelson | Chief Physics Officer and Member of Scientific Advisory Board |
Yael Zeiger | Corporate Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 21, 2024 | 6-K | Report of foreign issuer |
Oct 10, 2024 | 6-K | Report of foreign issuer |
Sep 20, 2024 | 6-K | Report of foreign issuer |
Aug 22, 2024 | 6-K | Report of foreign issuer |
Aug 14, 2024 | 6-K | Report of foreign issuer |
Aug 14, 2024 | 6-K | Report of foreign issuer |
Jun 25, 2024 | 6-K | Report of foreign issuer |
May 21, 2024 | 6-K | Report of foreign issuer |
May 20, 2024 | 6-K | Report of foreign issuer |
May 13, 2024 | 6-K | Report of foreign issuer |